REGULATORY

MHLW Starts Inviting Coronavirus Vaccine Developers after 2nd Extra Budget Passed

June 15, 2020

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Now that Japan’s Diet has passed a draft second extra budget for FY2020 aimed at cushioning the impact of the coronavirus outbreak, the Ministry of Health, Labor and Welfare (MHLW) has started inviting applications from companies seeking funding from the…

To read the full story

Japan to Grant Total of 90 Billion Yen to 6 Firms for COVID-19 Vaccine Production
August 11, 2020
Health Minister Asks Makers to Boost Syringe, Needle Production for Coronavirus Vaccines
July 15, 2020

REGULATORY

LDP Panel Finalizes Honebuto Proposal on Preventive Care, Adds Obesity Focus
June 5, 2026
Ex-GSK Japan Head Calls for End to "Obsolete" 14-Day Prescription Limit
June 5, 2026
Trazenta Generic Outlook Remains Clouded as Court Upholds Treatment-Method Patents
June 4, 2026
LDP Generic Caucus Wants Swift Disclosure of Company Indicator Ratings
June 4, 2026
LDP Social Security Panel Pushes Greater Reward for Innovation: Honebuto Proposal
June 3, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Are Technical Discussions Enough for Japan’s CEA System?

By Ken Yoshino

Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…